NASDAQ:MESO
Mesoblast Ltd Stock News
$7.35
+0.330 (+4.70%)
At Close: May 17, 2024
Mesoblast Financial Results and Corporate Update Webcast
07:38pm, Sunday, 26'th Feb 2023
NEW YORK, Feb. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation
Mesoblast Limited (MESO) Upgraded to Buy: Here's What You Should Know
01:32pm, Thursday, 15'th Dec 2022
Mesoblast Limited (MESO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Mesoblast Limited (MESO) Q1 2023 Earnings Call Transcript
08:50am, Wednesday, 23'rd Nov 2022
Mesoblast Limited (NASDAQ:MESO ) Q1 2023 Results Conference Call November 22, 2022 4:30 PM ET Company Participants Dr. Silviu Itescu - CEO and MD Andrew Chaponnel - Interim CFO Dr. Eric Rose - Chief M
Mesoblast Financial Results and Corporate Update Webcast
06:00am, Monday, 21'st Nov 2022
NEW YORK, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation
Mesoblast Limited (MESO) Q4 2022 Earnings Call Transcript
10:28pm, Tuesday, 30'th Aug 2022
Mesoblast Limited (NASDAQ:MESO ) Q4 2022 Earnings Conference Call August 30, 2022 6:30 PM ET Company Participants Silviu Itescu - CEO and MD Andrew Chaponnel - Interim CFO Eric Rose - Chief Medical Of
Mesoblast Corporate Update and Financial Results Webcast
08:14pm, Monday, 29'th Aug 2022
NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation
These were the best performing ASX 200 shares last week 12 March 2022
10:00pm, Friday, 11'th Mar 2022 The Motley Fool Australia
Mesoblast limited (ASX:MSB) and St Barbara Ltd (ASX:SBM) shares were among the best perfomers on the ASX 200 last week…
Mesoblast Earnings, Revenue Beat in Q2 By Investing.com
06:08am, Friday, 25'th Feb 2022 Investing.com
Mesoblast Earnings, Revenue Beat in Q2
Mesoblast GAAP EPS of -$4.00, revenue of $2.38M
10:46pm, Thursday, 24'th Feb 2022 Seeking Alpha
Mesoblast press release (MEOBF): Q2 GAAP EPS of -$4.00.Revenue of $2.38M (+6.3% Y/Y).
Operational Highlights and Financial Results for the Period Ended December 31, 2021
10:30pm, Thursday, 24'th Feb 2022 GlobeNewswire
Mesoblast Prepares for Resubmission of Biologics License Application Mesoblast Prepares for Resubmission of Biologics License Application
Mesoblast Corporate Update and Financial Results Webcast
05:57am, Thursday, 24'th Feb 2022
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation
Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohn''s Colitis After Direct Injection of Remestemcel-L by Colonoscopy
11:19pm, Sunday, 20'th Feb 2022 Benzinga
NEW YORK, Feb. 20, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO , ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced positive results from an interim analysis of the first patient cohort in the randomized, controlled study of remestemcel-L by direct endoscopic delivery to areas of inflammation in patients with medically refractory ulcerative colitis or Crohn''s colitis. A single local delivery of remestemcel-L by colonoscopy resulted in rapid mucosal healing and disease remission in these refractory patients at high risk of progression to surgery. The results of the first cohort of patients were presented at the 17 th Congress of European Crohn''s and Colitis Organisation (ECCO), February 16-19, by the trial''s lead investigator Dr. Amy L. Lightner, Associate Professor of Surgery in the Department of Colon and Rectal Surgery at Cleveland Clinic and were published in the Journal of Crohn''s and Colitis. 1,2 "Mesenchymal stromal cells (remestemcel-L) offer a safe therapeutic for the treatment of medically refractory Ulcerative Colitis and Crohn''s colitis," said Dr.
Mesoblast to Participate in Edison Group's Global Healthcare “Open House” Virtual Conference From January 25-27th, 2022
06:45pm, Monday, 24'th Jan 2022
NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it is participating in E
Single Dose Of Mesoblast's Cell Therapy Shows Durable Reduction In Back Pain
06:49am, Wednesday, 12'th Jan 2022
Mesoblast Limited (NASDAQ: MESO) announced 36-month follow-up results from the 400-subject Phase 3 trial of its allogeneic cell therapy rexlemestrocel-L in patients with chronic low back pain (CLBP
Mesoblast (NASDAQ:MESO) Stock Rating Lowered by Zacks Investment Research
06:14am, Sunday, 19'th Dec 2021 Transcript Daily
Mesoblast (NASDAQ:MESO) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Friday, Zacks.com reports. According to Zacks, Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on []
